Načítá se...
Recent advances on blinatumomab for acute lymphoblastic leukemia
Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are...
Uloženo v:
| Vydáno v: | Exp Hematol Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6833142/ https://ncbi.nlm.nih.gov/pubmed/31709129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0152-y |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|